Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dynamiker Biotechnology (Tianjin) Co Current Ratio?
Dynamiker Biotechnology (Tianjin) CoBJSE:920009 46 Current Ratio is 13.65 as of Mar. 2026, which is 113% above its 10-year median of 6.40. GuruFocus rates BJSE:920009 with a GF Score™ of 46/100. The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, Dynamiker Biotechnology (Tianjin) Co ranks better than 95.88% on this metric.
Dynamiker Biotechnology (Tianjin) Co has a current ratio of 13.65. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
BJSE:920009's Current Ratio is ranked better than 95.88% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.975
vs BJSE:920009: 13.65
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dynamiker Biotechnology (Tianjin) Co Current Ratio Related Terms
Dynamiker Biotechnology (Tianjin) Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynamiker Biotechnology (Tianjin) Co Current Ratio Chart
BJSE:920009 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Dynamiker Biotechnology (Tianjin) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynamiker Biotechnology (Tianjin) Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynamiker Biotechnology (Tianjin) Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dynamiker Biotechnology (Tianjin) Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) has a Current Ratio of 13.65 as of Mar. 2026. This is 113% above median its historical median of 6.40. Over the past decade, Dynamiker Biotechnology (Tianjin) Co's Current Ratio has ranged from 3.18 to 13.65. According to the industry distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #41 out of 996 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Dynamiker Biotechnology (Tianjin) Co's Current Ratio too high?
Dynamiker Biotechnology (Tianjin) Co's current Current Ratio of 13.65 is 113% above median its 10-year median of 6.40. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 13.65. The Drug Manufacturers industry median Current Ratio is 1.98. Dynamiker Biotechnology (Tianjin) Co's value of 13.65 is 591.1% above this industry median. Based on the distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #41 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dynamiker Biotechnology (Tianjin) Co has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Dynamiker Biotechnology (Tianjin) Co's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dynamiker Biotechnology (Tianjin) Co ranks #41 out of 996 companies for Current Ratio. This places Dynamiker Biotechnology (Tianjin) Co in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.98. Dynamiker Biotechnology (Tianjin) Co's value of 13.65 is 591.1% above this benchmark. Historically, Dynamiker Biotechnology (Tianjin) Co's own Current Ratio has ranged from 3.18 to 13.65 over the past decade. While the company's 10-year median is 6.40 vs. the industry median of 1.98, Dynamiker Biotechnology (Tianjin) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.98, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynamiker Biotechnology (Tianjin) Co's current Current Ratio of 13.65 is 591.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynamiker Biotechnology (Tianjin) Co's current Current Ratio is 13.65, which is 113% above median its own 10-year median of 6.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynamiker Biotechnology (Tianjin) Co stock overvalued right now?
Dynamiker Biotechnology (Tianjin) Co (BJSE:920009) has a current Current Ratio of 13.65. The current Current Ratio is 13.65, which is 113% above median its 10-year median of 6.40 and 591.1% above the Drug Manufacturers industry median of 1.98. Dynamiker Biotechnology (Tianjin) Co's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dynamiker Biotechnology (Tianjin) Co (BJSE:920009), the current Current Ratio is 13.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dynamiker Biotechnology (Tianjin) Co Ltd specializes in R&D, production, and sales of early serological diagnosis of invasive mycosis and in vitro diagnostic products for other pathogenic microorganisms.
46GF Score
Get the complete analysis for BJSE:920009
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920009 has been successfully added to your 
